Name | 2-[(2S)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide hydrochloride (1:2) |
---|---|
Synonyms |
1H-Benzimidazole-4-carboxamide, octahydro-2-(2-methyl-2-pyrrolidinyl)-
2-(2-Methyl-2-pyrrolidinyl)octahydro-1H-benzimidazole-4-carboxamide |
Description | PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with Kis of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC50 of 3 nM in a cell based assay of PARP activity[1]. |
---|---|
Related Catalog | |
Target |
PARP2:2 nM (Ki) PARP1:5 nM (Ki) |
In Vivo | PARP-2/1-IN-2 (Compound 4a) (25 or 50 mg/kg; i.p.) 在 Cisplatin (HY-17394) 和 Oxaliplatin (HY-17371) 诱导的小鼠神经病变中减轻疼痛[1]。 Animal Model: Male C57BL6J mice, Cisplatin (HY-17394) and Oxaliplatin (HY-17371)-induced painful neuropathy models[1] Dosage: 25 mg/kg or 50 mg/kg Administration: Intraperitoneal injection, two days prior to treatment with Cisplatin or oxaliplatin, with administration continuing by i.p. injection along with the Cisplatin or oxaliplatin regimen (5 days, followed by 5 days of rest, for two weekly cycles) Result: Does not attenuate Cisplatin and Oxaliplatin-induced body weight loss. Does not Affect the decline in exploratory behavior associated with Cisplatin and Oxaliplatin Treatment. Attenuates mechanical allodynia in Cisplatin and Oxaliplatin-induced neuropathy. Attenuates thermal hyperalgesia in Cisplatin-induced neuropathy. Attenuates cold hyperalgesia associated with Oxaliplatin-induced neuropathy. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 466.4±45.0 °C at 760 mmHg |
Molecular Formula | C13H24N4O |
Molecular Weight | 252.356 |
Flash Point | 235.9±28.7 °C |
Exact Mass | 252.195007 |
LogP | -0.88 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.522 |